Allogeneic Hematopoietic Cell Transplantation for Acute Megakaryocytic Leukemia: A Single Center Study
Authors: Suryaprakash Shruthi , Bi Yu , Selukar Subodh , Keerthi Dinesh , Qudeimat Amr , Talleur Aimee C. , Mamcarz Ewelina K. , Srinivasan Ashok , Renee Madden , Epperly Rebecca , Naik Swati , Gottschalk Stephen , Triplett Brandon M , Sharma Akshay 
Published: December 2023

Introduction

Acute megakaryocytic leukemia (AMKL) comprises 4-15% of all acute myeloid leukemia (AML) diagnoses in pediatric patients. Unlike patients with Down syndrome who have a &gt;80% expected survival with dose-reduced chemotherapy, the 5-year overall survival (OS) in patients with de novo AMKL is dismal and ranges between 14-49%. While treatment intensification has marginally improved the outcome of these patients over the last few decades, the role of hematopoietic cell transplantation (HCT) in these patients in first complete remission (CR) is often debated. To better define the role of HCT, we evaluated the outcomes of pediatric patients who underwent their first HCT for AMKL at our institution from October 1990 to January 2021.

Methods

We conducted a retrospective analysis using patient, disease, and transplant-related data collected during routine clinical care and evaluated these variables for their prognostic value. Kaplan-Meier curves were generated to estimate survival probabilities in pre-specified groups and compared using the log-rank test. Multivariable analysis was performed using Cox proportional hazards models to assess the role of various patient and transplant-related factors on survival. The cumulative incidence of relapse (with death as competing risk) was estimated by the Fine-Gray multivariable models and compared using Gray's test.

Results

Our study included 53 patients. The median age at HCT was 2.3 (range 0.9-19.7) years. The median time of follow-up was 10.3 (range 0.9-346.6) months. At the time of HCT, 56.6% of patients were in CR1, 5.7% were in CR2 and 37.7% had active/refractory disease. Nine (17%) patients received an HCT from a matched sibling donor, 25 (47.2%) from a matched unrelated donor, and 19 (35.8%) from a haploidentical donor. Twenty-two (41.5%) patients relapsed after HCT at a median duration of 2.8 (range 0.6-10.5) months, and 31 (58.5%) patients died at a median duration of 4.3 (range 0.9-15.9) months. The one-year OS estimates trended higher in patients undergoing transplant in more recent decades (1990-2000: 32%, 2000-2010: 46%, 2010-2020: 67%; P = 0.2). Patients who underwent HCT in CR had a significantly higher 1-year OS (57% versus 30%; P &lt; 0.001) and decreased rate of relapse (24% versus 70%; P &lt; 0.001) compared to those who underwent HCT with active/refractory disease. Similarly, in multivariable analysis, being in CR during HCT was associated with improved OS (Hazard Ratio [HR] 0.17, 95% Confidence Interval [CI] 0.07-0.41) and decreased risk of relapse (HR 0.18, 95% CI 0.07-0.46) after adjusting for other pre-specified variables.

Conclusion

While the overall outcome of patients who undergo HCT for AMKL has improved in the last few decades, it remains suboptimal. Patients who underwent HCT in CR had superior outcomes. Our data supports the notion that patients with de novo AMKL would benefit from HCT when they first achieve CR while we await novel strategies in treating relapsed or refractory AMKL.